3i continues to support strategic M&A activity across its private equity portfolio

3I

3i Group plc (“3i Group”) announces that four of its portfolio companies have recently made significant bolt-on acquisitions, expanding their geographies, capabilities and product ranges.

GartenHaus, the leading online retailer of garden homes, sheds and saunas in the DACH region in which 3i invested in September 2020, has acquired Polhus, a leading online retailer of garden houses and related products based in Sweden. Combined, GartenHaus and Polhus will be the pure-play, online market leader in both the German-speaking and Scandinavian regions.

Havea, a European leader in natural health products in which 3i invested in 2016, has acquired Laudavie, which includes Calmosine, the French specialist in children’s food supplements. Combined, Havea and Laudavie will become a leader in the babycare market in France. This is Havea’s fourth acquisition since 3i’s investment following the acquisitions of Aragan, Densmore and Pasquali Healthcare.

Cirtec, a leading global provider of outsourced medical device and components design, engineering and manufacturing in which 3i invested in 2017, has acquired NovelCath, a fast growing catheter-based delivery systems manufacturer based in Minnesota. The acquisition will enable Cirtec to further vertically expand within the core structural heart end market while increasing its existing exposure to other attractive segments including the electrophysiology, neurovascular and peripheral vascular markets. This is Cirtec’s seventh acquisition since 3i’s original investment.

Royal Sanders, a leading European private label and contract manufacturing producer of personal care products, has signed the acquisition of Royal Herkel, a private label and contract manufacturing producer of nutritional supplements, medical devices, pharmaceutical and cosmetic products based in the Netherlands. The acquisition expands Royal Sanders’ offering into vitamins, minerals and supplements, which is an attractive growth segment and a highly fragmented market. This is Royal Sanders’ second significant acquisition since 3i’s investment in 2018.

Simon Borrows, Chief Executive, 3i Group, commented: “During a challenging period, we have maintained our focus on enhancing the value of our portfolio through buy-and-build opportunities for our platform assets. These four strategic acquisitions represent significant milestones in the growth and internationalisation of GartenHaus, Havea, Cirtec Medical and Royal Sanders.”

-ends-

Download this press release   

 

For further information, contact:

3i Group plc

Silvia Santoro
Investor enquiries
Tel: +44 20 7975 3258
Email: silvia.santoro@3i.com
Kathryn van der Kroft
Media enquiries
Tel: +44 7721 886 304
Email: kathryn.vanderkroft@3i.com

 

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, specialising in core investment markets in Northern Europe and North America.

3i’s Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of mid-market companies with an EV typically between €100m – €500m. We back international growth plans, providing access to our network and expertise to accelerate the growth of companies across the consumer, industrial, healthcare and business and technology services industries.

For further information, please visit: www.3i.com

Regulatory information

This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group, and recommendations of 3i Investments plc, advised by 3i France and 3i Benelux.

Categories: News

Tags:

Diabeloop SA. and SFC Fluidics Inc. announce development agreement for the United States

Supernova Invest

SFC Fluidics Inc., developer of an Alternate Controller Enabled (ACE)
insulin delivery pod and Diabeloop, pioneer in therapeutic artificial
intelligence, are partnering to integrate the SFC ACE insulin pod into
Diabeloop’s Automated Insulin Delivery (AID) solution. The
agreement includes a full US-adaptation of the system.
A common mission: bring the next generation of diabetes management
to patients with type 1 diabetes in the United States.


Diabeloop is developing interoperable solutions, based on a proprietary self-learning algorithm,
for diabetes management. Both DBLG1 ® , their first product, and DBL-hu (for highly unstable Type 1
diabetes) have received CE-marking and will be deployed in Europe in 2021.
The technology developed by Diabeloop – an algorithm hosted in a dedicated handset – wirelessly
communicates with a continuous glucose monitoring device (CGM) and an insulin pump in an AID
(closed-loop) system. Diabeloop’s artificial intelligence analyzes glucose data, calculates the proper
dose of insulin to be administered and instructs the pump to deliver it, thus automating the treatment.
The agreement signed today covers the development of a system integrating the SFC insulin pump as
an Alternate Controller-Enabled 1 (ACE) insulin pump.
SFC’s ACE insulin delivery pod (“Panda™”) is intended for the subcutaneous delivery of insulin at set
and variable rates for the management of diabetes mellitus in persons requiring insulin. Its advanced
microfluidic pumping system (ePump®) is designed to provide accurate delivery of extremely small
doses of insulin without the resolution limits inherent in other commercially-available delivery devices.
SFC believes its technology will effectively eliminate 95% of over and under dispenses of insulin.
SFC’s proprietary Dispense Confirmation Sensor (DCS™) represents a differentiating technology that
can detect flow or no flow conditions of insulin in real-time. The DCS will quickly signal a lack of
dispense for any reason. SFC received the US Food and Drug Administration’s breakthrough device
designation for its Panda™ insulin delivery pod on November 5, 2020.
“We are encouraged that our relationship with Diabeloop continues to progress towards a meaningful
goal of a marketed artificial pancreas in the US” , commented Don Jackson, CFO of SFC .

A fully integrated AID system tailored to the US market


Diabeloop and SFC Fluidics share the vision of advancing diabetes therapy for patients through
state-of-the-art technologies and a fully automated approach.
SFC Fluidics and Diabeloop continue their relationship, which started with a project initially funded by
the JDRF.
“JDRF is committed to improving the lives of people with type 1 diabetes by supporting innovations in
diabetes treatments. We are excited to see the partnership between Diabeloop and SFC Fluidics
continue to flourish and look forward to the development of a novel artificial pancreas system that can
improve the health and quality of life of people living with T1D ”, said Jonathan Rosen , Ph.D., Associate
Director of Research at JDRF.
SFC would also like to acknowledge the National Institutes of Health, including the National Institute
of Diabetes and Digestive and Kidney Diseases, for help in funding the development of various
aspects of the ACE pod 2 .
The new agreement includes the adaptation of Diabeloop’s algorithm and data visualization platform
YourLoops™, the integration of the SFC ACE insulin pump, as well as the application for regulatory
approval and the conduct of non-clinical and clinical trials, all following US Food and Drug
Administration regulations 3 .
“We are delighted to reinforce our collaboration with this strong partner. The conclusion of this
agreement with SFC Fluidics, Inc. is a real mutual achievement, and for Diabeloop it is an additional
opportunity to enter the US market ”, commented Marc Julien, co-CEO of Diabeloop .


About Diabeloop
Diabeloop’s mission: to relieve people living with Type 1 diabetes from dozens of therapeutic decisions and
reduce their heavy mental burden. Initially conceived from a medical research project, Diabeloop was created
in 2015 by Dr. Guillaume Charpentier, now Chief Medical Officer, and Erik Huneker who has co-managed the
company with Marc Julien since 2016. This complementary management team works with experienced
partners, CEA-Leti (a research laboratory) and CERITD (a French research team of diabetologists).
In 2018, DBLG1 ® System, Diabeloop’s first medical device for automated diabetes management, obtained CE
marking, followed by DBL-hu, its solution for highly unstable Type 1 diabetes management in 2020.
A second round of financing of 31 million euros concluded in November 2019 to speed up the international
commercial rollout of the DBLG1 ® iController and support an ambitious R&D program.
Today, Diabeloop gathers the personality, the passion and the skills of close to 100 talented individuals who
work hard to improve the quality of life for every person living with Type 1 diabetes.

About SFC Fluidics, Inc.
SFC Fluidics, Inc. has a mission to advance healthcare and improve quality of life through our enabling
microfluidic technologies. The company’s vision is to become a recognized global leader in drug delivery, with
a focus on insulin, where our unique product lines improve lifestyle and affordability. SFC Fluidics ® is a VIC

Categories: News

Tags:

Deluxe Acquires Sundog Media Toolkit

Platinum

UK firm provides mastering and versioning services for theatrical, television, and OTT content

LOS ANGELES, CA, JANUARY 07, 2021 – Deluxe, the global provider of digital and cloud-based solutions to the world’s leading content production studios and distributors, announced today their acquisition of UK-based Sundog Media Toolkit, Ltd. (“Sundog”). Financial terms were not disclosed.

Founded in 2013 by CEO Richard Welsh and CTO Chris Ralph, Sundog quickly established a market foothold with their highly automated, cloud-based platform that creates specialized multi-format, multi-language files for theatrical distribution and streaming platforms. Welsh and Ralph have joined Deluxe in senior executive positions.

“We are thrilled to welcome Richard, Chris, and the rest of the Sundog team into the Deluxe family. Sundog will provide us with an expansion and enhancement of our robust technology driven services, adding efficiency, speed, and scale,” said Cyril Drabinsky, CEO of Deluxe. “This acquisition confirms our commitment to innovation that puts us ahead of the increasing complexity and scale needs of our customers’ day and date multiplatform releases.”

“We are thrilled to welcome Richard, Chris, and the rest of the Sundog team into the Deluxe family. Sundog will provide us with an expansion and enhancement of our robust technology driven services, adding efficiency, speed, and scale,” said Cyril Drabinsky, CEO of Deluxe. “This acquisition confirms our commitment to innovation that puts us ahead of the increasing complexity and scale needs of our customers’ day and date multiplatform releases.”

“We’re delighted to be joining Deluxe. We established Sundog to bring advanced SaaS technology and workflows to the media industry and we’re very excited about taking the next steps on the Sundog journey together with Cyril and the Deluxe team,” said Welsh. “With our combined drive for innovation and Deluxe’s global footprint, we will be able to extend our cloud automation technologies to customers worldwide.”Deluxe provides the world’s leading content creators and distributors a portfolio of media services including Cinema (mastering, key generation and distribution to theaters), along with Localization & Fulfillment (subtitling, dubbing, encryption, transcoding and distribution of movies and tv content), Home Entertainment (compression, encoding and authoring), and digital asset management, virtual screening and live-streaming events via its One Showcase solution.

The Sundog technology, integrated with the overall Deluxe One workflow, will create the industry’s most sophisticated and comprehensive end-to-end solution for mastering content, including asset/library management, localization, and final delivery.

About Deluxe
Deluxe Media Inc. (Deluxe) provides innovative, secure distribution and localization services for studios, OTT platforms and content creators worldwide. Deluxe’s cloud-based solutions offer unprecedented flexibility and reach through its customizable, end-to-end solutions that enable customers to create, transform, and distribute content and immersive streaming experiences to audiences on a global scale.

Investor Relations
and Media Contacts:

Mark Barnhill
Partner
+1 310.228.9514 E-mail Mark

Dan Whelan
Principal
+1 310.282.9202 E-mail Dan

Categories: News

Tags:

PointClickCare Technologies Enters Next Phase of Growth with Minority Strategic Investment from New Investor Hellman & Friedman and Existing Investor Dragoneer Investment Group

JMI Equity

Investments Expected to Drive Further Expansion of PointClickCare Product Offerings and Accelerate Growth

MISSISSAUGA, Ontario–(BUSINESS WIRE)–PointClickCare Technologies, the leader in cloud-based healthcare software for the long-term and post-acute care market, today announced a minority strategic investment from affiliates of Hellman & Friedman LLC (“H&F”), a preeminent global private equity firm with a distinctive approach focused on investments in high-quality growth businesses, as well as an increased investment from Dragoneer Investment Group, a long-term-oriented investment firm with an extensive track record of investing in leading growth companies.

H&F will work with the PointClickCare leadership team to continue fueling growth and expanding the company’s product offerings. As part of the investment, Sameer Narang, Partner at H&F, will join the PointClickCare Board of Directors. PointClickCare Founders Mike and David Wessinger will continue to control and operate the company with the support of the Board of Directors.

“We are excited to welcome Hellman & Friedman as an investor in PointClickCare given its deep sector expertise and its collaborative partnership approach, and are delighted to officially welcome Sameer to our board,” said Mike Wessinger. “This investment, along with Dragoneer’s increased stake, will help us accelerate our growth and expansion across the healthcare continuum, and enable us to continue delivering on our commitment to our customers’ success – particularly at a time when the need for more seamless care through innovative technology is paramount.”

“H&F is thrilled to join PointClickCare’s investor base. We believe there is significant growth opportunity ahead given the company’s exceptional customer relationships, strong product suite and leading market position in the post-acute ecosystem,” said Narang. “PointClickCare sits at the intersection of our healthcare and software investment efforts, exhibiting all the compelling characteristics we seek out when investing in vertical-market category leaders. We look forward to collaborating with the team and believe we are uniquely positioned to further accelerate the Company’s expansion, for the benefit of its customers and the broader healthcare industry.”

“As the largest outside investor in PointClickCare, we are thrilled to be expanding our investment in PointClickCare,” said Christian Jensen, Partner at Dragoneer and member of the PointClickCare Board of Directors. “We look forward to continuing to support PointClickCare as it builds on its already impressive momentum and delivers even more of the hallmark innovation that has created fierce loyalty among its customers.”

PointClickCare’s cloud-based healthcare software platform provides the core clinical and administrative system of record and a comprehensive suite of workflow management tools for skilled nursing facilities, senior living communities and home health agencies. PointClickCare currently serves over 21,000 long-term and post-acute care providers, including approximately 65% of skilled nursing facilities in the United States.

PointClickCare recently acquired Collective Medical, the leading network-enabled platform for real-time cross-continuum care coordination. Together, PointClickCare and Collective Medical will provide diverse care teams across the continuum of acute, ambulatory, and post-acute care with point-of-care access to deep, real-time patient insights at any stage of a patient’s healthcare journey, enabling better decision-making and improved clinical outcomes at lower cost.

“We would also like to take this opportunity to thank JMI Equity, which has undoubtedly contributed to the success of PointClickCare and our customers by enabling us to expand the breadth of our solution suite and meet the evolving needs of long-term care providers,” continued Wessinger. “Most importantly, we thank them for believing in our vision. We look forward to building on the continued leadership momentum we have created and are pleased to have the H&F team on board, alongside the continued support of Dragoneer Investment Group and JMI Equity, as we approach our next stage of growth.”

UBS Investment Bank provided financial advisory services and Goodwin Procter LLP provided legal advisory services to PointClickCare in the successful financing and facilitation of the equity transactions.  Evercore provided financial advisory services to JMI Equity.

To learn more about PointClickCare, visit www.pointclickcare.com.

About PointClickCare

With a suite of fully-integrated applications powered by cloud-based healthcare software, PointClickCare leads the way in helping care providers connect, collaborate, and share data within their network. Over 21,000 long-term and post-acute care providers, including skilled nursing facilities, senior living communities, and home health agencies use PointClickCare today, making it the North American healthcare IT market leader for the senior care industry. For more information on PointClickCare’s software solutions, visit www.pointclickcare.com.

Contacts

Tania DiVito
Corporate Communications Manager, PointClickCare
Tania.divito@pointclickcare.com
905-858-8885 x1997
800-277-5889 x1997

Categories: News

Liva Healthcare secures €24.5m funding – led by Verlinvest – to drive European leadership in digital chronic disease prevention and management

Verlinvest

Liva Healthcare (“Liva”), a European market leader in scalable digital health coaching, has secured a new funding round of EUR 24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.

Liva is a health tech company headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.

The on-going Covid-19 pandemic has led to a significant shift in acceptance of remote healthcare by European consumers. This shift in acceptance and the subsequent patient behaviour has given Liva a significant increase in interest from public healthcare providers and life science companies in 2020.

Liva is used by clients such as Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia and several other key players in public healthcare, insurance and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being setup in Germany and Switzerland.

Read more at Businesswire.com

Categories: News

Tags:

Gilde Healthcare leads $28 million financing in Volta Medical to revolutionize persistent AFib ablation

GIlde Healthcare

Marseille (France) – Utrecht (the Netherlands) – Volta Medical, a French-based HealthTech startup, pioneering novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised an 28 million USD financing round led by Gilde Healthcare. The new capital will allow the company to establish its revolutionary FDA-cleared and CE marked VX1 AI software solution as a new standard of care, pursue further R&D activities and start to roll out commercial activities across the US and Europe. Recruitment for TAILORED-AF, an international multicenter trial has already started. Volta Medical will be welcoming two new Board members. Janke Dittmer, General Partner at Gilde Healthcare, has been nominated as a board member and former medical device industry top executive, Denis Gestin, as an independent board member.

AF affected approximately 6 million patients in the US in 2019 and is estimated to double by 2060. 120,000-215,000 new cases are projected to occur in this part of the world each year reaching a total AF patient population level of 14-17 million. After developing the first commercially available AI software to help electrophysiologists improve management of cardiac arrythmias, Volta Medical is now preparing to transform the way ablation procedures will take place in the future.

About atrial fibrillation (AFib or AF)

AF can be considered an “electrical storm” in the atria in which all synchronized activities have disappeared, and the necessary coordination of the contraction stops. This can lead to a number of symptoms including palpitations, shortness of breath, and in some patients, heart failure. AF is also a major risk factor for stroke, as stagnant blood in the atrium during AF may lead the formation of a clot, that can migrate to the brain.

AF affected approximately 6 million patients in the US in 2019 and is estimated to double by 2060. 120,000-215,000 new cases are projected to occur in this part of the world each year reaching a total AF patient population level of 14-17 million. A study in the UK concluded that AFib is an extremely costly public health problem. Evidence suggests a higher prevalence of AFib in patients with hypertension, heart failure, coronary heart disease, obesity, diabetes. In addition, recent studies show that 20-30% of patients with ischemic stroke have had AFib before, during or after the initial event. AF increases the likelihood of stroke by four to five times and AFib-induced strokes that are generally associated with more severe damage.
About Volta Medical
Founded by three physicians and a data scientist in 2016 in Marseille, Volta Medical is a HealthTech company developing AI software solutions to assist cardiac electrophysiologists in the operating room. Volta’s overarching goal is to drastically improve cardiac arrythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. Its first product, VX1, assists cardiologists for the real-time identification of specific abnormal electrograms, known as dispersed electrograms.

For more information, visit the company’s website at www.volta-medical.com.

About the VX1 AI software
VX1 consists of a highly innovative AI algorithm that is compatible with most readily available multipolar catheters and technologies currently used in operating rooms or electrophysiology labs. The VX1 software analyzes the patient’s electrograms in real-time to identify specific electrograms known as dispersed electrograms. It also provides a cycle length estimation from electrograms recorded with the mapping and the coronary sinus catheters.

The clinical significance of utilizing the VX1 software to help identify areas with intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion for catheter ablation of atrial arrhythmias, such as atrial fibrillation, has not been established by clinical investigations.

VX1 is a medical device which is FDA cleared and has a CE mark.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Leading SASE Cloud Security Provider iboss Raises $145 Million to Support Company’s Rapid Growth in $25B Expanding Market

Franciso Partners

BOSTON — iboss, the leader in cloud delivered network security, announces it has raised $145 million in new funding. The financing will be used to support the company’s rapid growth as organizations increasingly recognize iboss as the leading provider of cutting-edge network security through the cloud.

The new funding comes as the COVID-19 pandemic has accelerated the ongoing shift to cloud-based cybersecurity providers. As organizations of all sizes continue to rely more on distributed and dispersed workforces, they need cybersecurity solutions that follow the user — regardless of where they are located or what device they are using — with the same security procedures and protection that they would have in the office. The unique, cloud-native iboss platform constantly defends organizations from cyberattacks by screening and securing all internet traffic in the cloud, regardless of device or location.

“COVID-19 has exposed massive vulnerabilities with outdated, hardware-based cybersecurity solutions and accelerated the timeline of moving away from the old method of securing physical office perimeters,” said iboss CEO Paul Martini. “Implementing modern architecture that provides network security in the cloud is the best way to ensure safety and productivity, even as remote workers rely more and more on fast connections for things like video meetings and online productivity apps.”

iboss seamlessly enables a consolidation of networking and cutting-edge security into a Secure Access Service Edge (SASE) model that operates and provides cybersecurity protection in the cloud. As dispersed workforces increasingly connect to cloud applications such as Microsoft Office 365, Zoom and others, iboss provides infinite scalability while ensuring fast, secure and compliant connections. The iboss platform directly connects users to offices as well as cloud applications, eliminating the need to route internet traffic through centralized, on-premise appliances.

By delivering network security as a service via the cloud, iboss eliminates the need for expensive, hardware-based security and legacy infrastructure, which improves productivity, end-user experience and business outcomes for organizations leveraging cloud applications. The company’s proprietary architecture is built for the cloud from the ground up, allowing organizations to migrate security features and policies — such as web gateway proxies, network firewalls and Zero Trust Network Access — directly to the cloud.

“iboss has created the largest, most modern and comprehensive SASE security platform on the market and is the only platform that can fully transition organizations from on-prem security appliances to SaaS security delivered in the cloud,” said Dave DeWalt, Founder of NightDragon and Co-Chairman of iboss. “What makes this stronger is that iboss is an open security platform that allows organizations to apply the security engines and log analytics platforms of their choosing compared to existing closed SASE solutions that lack this flexibility and restrict better security due to lack of collaboration with top cybersecurity intelligence vendors.”

“We are thrilled to partner with iboss and participate in this growth financing,” said Scott Eisenberg, Head of Credit at Francisco Partners. “As the traditional enterprise perimeter dissolves, security solutions need to enable safe access to apps and services anytime, anywhere. iboss’ cloud-first solution was designed to address this transformational infrastructure shift.”

An open platform means that by leveraging iboss as the secure connectivity foundation for an organization, it allows flexibility in choice for malware engines, malware feeds, threat intelligence and log analytics solutions by allowing them to easily connect through the iboss SASE service. This results in more collaboration between the leading cybersecurity and technology vendors resulting in better protection and efficacy while giving organizations choice and flexibility as they transition into the cloud era.

Momentum Cyber served as exclusive financial advisor and Goodwin Procter LLP served as legal counsel to iboss for this financing. Francisco Partners was advised by Akin Gump Strauss Hauer & Feld LLP as its legal counsel.

About iboss, Inc. iboss is a cloud security company that provides organizations and their employees fast and secure access to the Internet on any device, from any location, in the cloud. The iboss cloud platform provides network security as a service, delivered in the cloud, as a complete SaaS offering. This eliminates the need for traditional network security appliances, such as firewalls and web gateway proxies, which are ineffective at protecting a cloud-first and mobile world. Leveraging a purpose-built cloud architecture backed by over 190 issued and pending patents and more than 100 points of presence globally, iboss protects more than 4,000 organizations worldwide, including a large number of Fortune 50 companies. To learn more, visit https://www.iboss.com.

About NightDragon NightDragon is an investment firm focused on investing in growth and late-stage companies within the cybersecurity, safety, security, and privacy industry. Its flexible model allows it to lead or co-invest alongside leading venture capital and private equity firms in the pursuit of driving growth and increasing shareholder value. NightDragon is unique in providing deep operational expertise in cybersecurity gained by its founders Dave DeWalt and Ken Gonzalez from years serving as senior executives leading technology companies such as Documentum, EMC, Siebel Systems (Oracle), McAfee, Mandiant, Avast, and FireEye.

About Francisco Partners Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch 20 years ago, Francisco Partners has raised over $24 billion in committed capital and invested in more than 300 technology companies, making it one of the most active and longstanding investors in the technology industry. The firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit https://www.franciscopartners.com/.

Categories: News

Tags:

PointClickCare Technologies Enters Next Phase of Growth with Minority Strategic Investment from New Investor Hellman & Friedman and Existing Investor Dragoneer Investment Group

JMI Equity

Investments Expected to Drive Further Expansion of PointClickCare Product Offerings and Accelerate Growth

MISSISSAUGA, Ontario–(BUSINESS WIRE)–PointClickCare Technologies, the leader in cloud-based healthcare software for the long-term and post-acute care market, today announced a minority strategic investment from affiliates of Hellman & Friedman LLC (“H&F”), a preeminent global private equity firm with a distinctive approach focused on investments in high-quality growth businesses, as well as an increased investment from Dragoneer Investment Group, a long-term-oriented investment firm with an extensive track record of investing in leading growth companies.

H&F will work with the PointClickCare leadership team to continue fueling growth and expanding the company’s product offerings. As part of the investment, Sameer Narang, Partner at H&F, will join the PointClickCare Board of Directors. PointClickCare Founders Mike and David Wessinger will continue to control and operate the company with the support of the Board of Directors.

“We are excited to welcome Hellman & Friedman as an investor in PointClickCare given its deep sector expertise and its collaborative partnership approach, and are delighted to officially welcome Sameer to our board,” said Mike Wessinger. “This investment, along with Dragoneer’s increased stake, will help us accelerate our growth and expansion across the healthcare continuum, and enable us to continue delivering on our commitment to our customers’ success – particularly at a time when the need for more seamless care through innovative technology is paramount.”

“H&F is thrilled to join PointClickCare’s investor base. We believe there is significant growth opportunity ahead given the company’s exceptional customer relationships, strong product suite and leading market position in the post-acute ecosystem,” said Narang. “PointClickCare sits at the intersection of our healthcare and software investment efforts, exhibiting all the compelling characteristics we seek out when investing in vertical-market category leaders. We look forward to collaborating with the team and believe we are uniquely positioned to further accelerate the Company’s expansion, for the benefit of its customers and the broader healthcare industry.”

“As the largest outside investor in PointClickCare, we are thrilled to be expanding our investment in PointClickCare,” said Christian Jensen, Partner at Dragoneer and member of the PointClickCare Board of Directors. “We look forward to continuing to support PointClickCare as it builds on its already impressive momentum and delivers even more of the hallmark innovation that has created fierce loyalty among its customers.”

PointClickCare’s cloud-based healthcare software platform provides the core clinical and administrative system of record and a comprehensive suite of workflow management tools for skilled nursing facilities, senior living communities and home health agencies. PointClickCare currently serves over 21,000 long-term and post-acute care providers, including approximately 65% of skilled nursing facilities in the United States.

PointClickCare recently acquired Collective Medical, the leading network-enabled platform for real-time cross-continuum care coordination. Together, PointClickCare and Collective Medical will provide diverse care teams across the continuum of acute, ambulatory, and post-acute care with point-of-care access to deep, real-time patient insights at any stage of a patient’s healthcare journey, enabling better decision-making and improved clinical outcomes at lower cost.

“We would also like to take this opportunity to thank JMI Equity, which has undoubtedly contributed to the success of PointClickCare and our customers by enabling us to expand the breadth of our solution suite and meet the evolving needs of long-term care providers,” continued Wessinger. “Most importantly, we thank them for believing in our vision. We look forward to building on the continued leadership momentum we have created and are pleased to have the H&F team on board, alongside the continued support of Dragoneer Investment Group and JMI Equity, as we approach our next stage of growth.”

UBS Investment Bank provided financial advisory services and Goodwin Procter LLP provided legal advisory services to PointClickCare in the successful financing and facilitation of the equity transactions.  Evercore provided financial advisory services to JMI Equity.

To learn more about PointClickCare, visit www.pointclickcare.com.

About PointClickCare

With a suite of fully-integrated applications powered by cloud-based healthcare software, PointClickCare leads the way in helping care providers connect, collaborate, and share data within their network. Over 21,000 long-term and post-acute care providers, including skilled nursing facilities, senior living communities, and home health agencies use PointClickCare today, making it the North American healthcare IT market leader for the senior care industry. For more information on PointClickCare’s software solutions, visit www.pointclickcare.com.

Contacts

Tania DiVito
Corporate Communications Manager, PointClickCare
Tania.divito@pointclickcare.com
905-858-8885 x1997
800-277-5889 x1997

Categories: News

Tags:

Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines

Healthcap

Aro’s proprietary Centyrin technology platform enables precise receptor-mediated delivery of RNA drugs to address intracellular gene targets

– Funding will help advance lead candidates into clinical development

Philadelphia, PA, January 5, 2021 – a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of an $88 million Series A financing. Northpond Ventures and Cowen Healthcare Investments led the round, with participation from HealthCap, BVF Partners L.P., and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), BioMotiv, LLC, and Ionis Pharmaceuticals, Inc. also participated in the round. Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease. The proceeds from the Series A will be used to advance the company’s lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders.

“Aro is poised to deliver on the promise of our Centyrin platform to enable more efficient and precise delivery of RNA drugs to extra-hepatic tissues. By exploiting new mechanisms of action, Centyrin-RNA conjugates have the potential to achieve superior efficacy and safety in treating intractable diseases,” said Susan Dillon, Ph.D., co-founder and chief executive officer of Aro. “We greatly appreciate the confidence our investors have in our vision. With their support, we can rapidly progress the development of our innovative drug discovery pipeline and ultimately deliver transformative genetic medicines to patients that desperately need them.”

Aro was founded in 2018 by Dr. Dillon and Karyn O’Neil, Ph.D., a co-inventor of the Centyrin platform.  Centyrins are small, exceptionally stable, engineered human proteins with several unique properties that make them ideally suited to target receptors on specific cells and deliver complex drug payloads to specific disease sites.

“Aro’s unique and proprietary Centyrin platform has significant potential in the treatment of rare diseases,” said Shaan Gandhi, M.D., D.Phil., director at Northpond Ventures, who has joined Aro’s board of directors. “The company has an experienced leadership team with a track record of success in drug discovery and clinical development. We look forward to supporting them as they develop bold therapies that could make a real difference in the lives of patients.”

“We are excited to invest in a company that is on the cutting edge in the development of genetic medicines,” said Kevin Raidy, managing partner of Cowen Healthcare Investments, who also joined Aro’s board of directors. “We look forward to working with the company as it strengthens and broadens its highly-differentiated Centyrin platform and are delighted to be part of the next chapter in Aro’s growth.”

About Aro Biotherapeutics

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases. For more information, visit www.arobiotx.com.

# # #

Media Contact

Mike Beyer

Sam Brown Inc.

mikebeyer@sambrown.com

312-961-2502

Categories: News

Tags:

AnaCap makes growth investment in leading German insurance broker MRH Trowe

Anacap

AnaCap Financial Partners (“AnaCap”), a leading financial services specialist mid-market private equity investor, today announces a significant growth investment into MRH Trowe (“MRHT”), an owner managed top-10 commercial lines insurance broker in Germany.

AnaCap will join the MRHT management team as a strategic growth partner with management remaining as the largest shareholder group in the company. The investment will enable the acceleration of an acquisitions pipeline alongside investment in talent, data management and the application of technology.

This transaction allows management to remain as long-term committed shareholders of the group while continuing to build a leading, German commercial lines insurance broker, supported by AnaCap as collaborative investment partners.

The deal follows AnaCap’s successful growth partnership with the management founders of heidelpay, a German payments company which was successfully sold to KKR last year.

MRH Trowe is one of the ten largest German industrial brokers. In addition to MRH Trowe Insurance Brokers GmbH, several specialist service providers for various segments operate under the umbrella of Mesterheide Rockel Hirz Trowe AG Holding. MRHT offers extensive expertise in practically all insurance lines for industrial and commercial customers as well as affluent private customers. The owner-managed company continues to pursue a consistent growth trajectory with a holistic advisory offer, specialised teams and a strong focus on digitisation at the interface of clients, brokers and insurers.

470 MRHT employees manage a premium volume of more than €300 million and helped to generate around €60 million of run-rate revenues in 2020. This represents an average annual growth rate of more than 20%, organically and inorganically, since 2017.

MRHT distributes its product offering through a strong network across 12 German cities nationwide and also has exclusive partnerships with more than 100 German savings banks.

As a specialist financial services investor, AnaCap will bring both capital and operational expertise to accelerate MRHT’s impressive growth through further acquisitions in the large and highly fragmented German commercial lines insurance broking market.

AnaCap will also support MRHT’s digitisation strategy, aiming to further develop their hybrid distribution model of tailored personal insurance broking as well as digital and online customer portals, claims settlement, reporting and cross-selling among other service offerings.

Ralph Rockel, Co-Founder of MRH Trowe, commented: “We are enormously excited about partnering with AnaCap for the next stage of our journey.  AnaCap has significant experience in the insurance market as well as a proven track record in building leading businesses both organically and through acquisition in the DACH region.  In addition, their expertise in the application of enabling technology will help us continue to gain market share and margins. We look forward to a dynamic outlook together.”

Tassilo Arnhold, Partner at AnaCap, commented: “The longer-term outlook for the insurance broking market in the DACH region is compelling. Our strategy is to partner with an excellent management team and to bring our experience of growth execution, as well as technological innovation in the insurance sector more generally, to support this outstanding growth opportunity. We anticipate working in tandem with the MRHT team over the coming years to accelerate a successful buy-and-build strategy in this attractive market.”

The investment was made from AnaCap Financial Partners III, L.P and financial details and terms of the transaction were not disclosed.

Jan 06 2021

Categories: News

Tags: